Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Status:
Completed
Trial end date:
2017-04-13
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to
evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in
patients with Type I and Type II HAE.